Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 7/2019

01-07-2019 | Insulins | Review Article

Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation

Authors: Lee S. Nguyen, Mathieu Vautier, Yves Allenbach, Noel Zahr, Olivier Benveniste, Christian Funck-Brentano, Joe-Elie Salem

Published in: Drug Safety | Issue 7/2019

Login to get access

Abstract

Inhibitors of mechanistic target of rapamycin (mTOR inhibitors) are used as antiproliferative immunosuppressive drugs and have many clinical applications in various drug combinations. Experience in transplantation studies has been gained regarding the side effect profile of these drugs and the potential benefits and limitations compared with other immunosuppressive agents. This article reviews the adverse effects of mTOR inhibitors in solid organ transplantation, with special attention given to mechanisms hypothesized to cause adverse events and their management strategies.
Literature
1.
Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot. 1975;28(10):721–6.CrossRef
2.
Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature. 1994;370(6484):71–5.CrossRefPubMed
3.
Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992;69(7):1227–36.CrossRefPubMed
4.
Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature. 1992;358(6381):70–3.CrossRefPubMed
5.
6.
Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013;23(1):53–62.CrossRefPubMed
7.
Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10(5):307–18.CrossRefPubMed
8.
9.
Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet (London, England). 2000;356(9225):194–202.CrossRef
10.
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet (London, England). 2011;377(9768):837–47.CrossRef
11.
Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7):1036–42.CrossRefPubMed
12.
Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB. Posttransplant anemia: the role of sirolimus. Kidney Int. 2009;76(4):376–82.CrossRefPubMed
13.
McDonald MA, Gustafsson F, Almasood A, Barth D, Ross HJ. Sirolimus is associated with impaired hematopoiesis in heart transplant patients? A retrospective analysis. Transpl Proc. 2010;42(7):2693–6.CrossRef
14.
MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271–80.CrossRefPubMed
15.
Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis and sirolimus—is iron the missing link? Nephrol Dial Transpl. 2010;25(5):1667–75.CrossRef
16.
Zhou J, Fan J, Wang Z, Wu Z-Q, Qiu S-J, Huang X-W, et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol. 2006;12(19):3114–8.CrossRefPubMedPubMedCentral
17.
Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transpl. 2004;4(12):2001–6.CrossRef
18.
Cahill BC, Somerville KT, Crompton JA, Parker ST, O’Rourke MK, Stringham JC, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transpl. 2003;22(2):169–76.CrossRef
19.
Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100(1):116–25.CrossRefPubMed
20.
Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, et al. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation. 2011;91(3):309–16.CrossRefPubMedPubMedCentral
21.
Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation. 2000;69(10):2085–90.CrossRefPubMed
22.
Ahya VN, McShane PJ, Baz MA, Valentine VG, Arcasoy SM, Love RB, et al. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transpl. 2011;30(2):175–81.CrossRef
23.
Eisenreich A, Celebi O, Goldin-Lang P, Schultheiss HP, Rauch U. Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel. Int Immunopharmacol. 2008;8(2):307–11.CrossRefPubMed
24.
Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051–8.CrossRefPubMed
25.
Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Luscher TF, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005;112(13):2002–11.CrossRefPubMed
26.
Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dialysis Transpl. 1998;13(12):3153–9.CrossRef
27.
de Fijter JW, Holdaas H, Oyen O, Sanders JS, Sundar S, Bemelman FJ, et al. Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE Trial. Am J Transpl. 2017;17(7):1853–67.CrossRef
28.
Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salame E, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial. Am J Transpl. 2017;17(7):1843–52.CrossRef
29.
Dong M, Parsaik AK, Eberhardt NL, Basu A, Cosio FG, Kudva YC. Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation. Diabet Med. 2012;29(7):e1–12.CrossRefPubMed
30.
Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19(7):1411–8.CrossRefPubMedPubMedCentral
31.
Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transpl. 2009;9(5):1115–23.CrossRef
32.
Holdaas H, Rostaing L, Seron D, Cole E, Chapman J, Fellstrom B, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation. 2011;92(4):410–8.CrossRefPubMed
33.
Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2):233–42.CrossRefPubMed
34.
Asleh R, Briasoulis A, Kremers WK, Adigun R, Boilson BA, Pereira NL, et al. Long-term sirolimus for primary immunosuppression in heart transplant recipients. J Am Coll Cardiol. 2018;71(6):636–50.CrossRefPubMed
35.
Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation. J Hepatol. 2012;56(1):288–90.CrossRefPubMed
36.
Vivarelli M, Dazzi A, Cucchetti A, Gasbarrini A, Zanello M, Di Gioia P, et al. Sirolimus in liver transplant recipients: a large single-center experience. Transpl Proc. 2010;42(7):2579–84.CrossRef
37.
Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes. 2008;57(4):945–57.CrossRefPubMed
38.
Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes. 2010;59(6):1338–48.CrossRefPubMedPubMedCentral
39.
Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transpl. 2003;3(2):178–85.CrossRef
40.
41.
Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol. 2006;17(8):2236–44.CrossRefPubMed
42.
43.
Elghazi L, Weiss AJ, Barker DJ, Callaghan J, Staloch L, Sandgren EP, et al. Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology. 2009;136(3):1091–103.CrossRefPubMed
44.
Altomare DA, Khaled AR. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem. 2012;19(22):3748–62.CrossRefPubMedPubMedCentral
45.
Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia. 2006;49(10):2341–9.CrossRefPubMed
46.
Kwon G, Marshall CA, Liu H, Pappan KL, Remedi MS, McDaniel ML. Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. J Biol Chem. 2006;281(6):3261–7.CrossRefPubMed
47.
Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23(2):201–29.CrossRefPubMed
48.
Mittelman SD, Bergman RN. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab. 2000;279(3):E630–7.CrossRefPubMed
49.
Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16(10):3128–35.CrossRefPubMed
50.
Lamming DW, Sabatini DM. A central role for mTOR in lipid homeostasis. Cell Metab. 2013;18(4):465–9.CrossRefPubMed
51.
Syed NA, Khandelwal RL. Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem. 2000;211(1–2):123–36.CrossRefPubMed
52.
Taha C, Liu Z, Jin J, Al-Hasani H, Sonenberg N, Klip A. Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem. 1999;274(46):33085–91.CrossRefPubMed
53.
Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transpl Rev (Orlando, Fla). 2014;28(3):126–33.CrossRef
54.
Holdaas H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transpl Rev (Orlando, Fla). 2015;29(2):93–102.CrossRef
55.
Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation. 2004;110(25):3858–65.CrossRefPubMed
56.
Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation. 2005;80(3):303–9.CrossRefPubMed
57.
Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation. 2001;72(7):1244–50.CrossRefPubMed
58.
Zimmermann A, Zobeley C, Weber MM, Lang H, Galle PR, Zimmermann T. Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation. Eur J Intern Med. 2016;29:104–9.CrossRefPubMed
59.
Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transpl. 2013;13(5):1203–16.CrossRef
60.
Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transpl. 2007;21(4):536–43.CrossRef
61.
Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transpl. 2008;8(7):1384–92.CrossRef
62.
Charlton M, Rinella M, Patel D, McCague K, Heimbach J, Watt K. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study. Transplantation. 2017;101(12):2873–82.CrossRefPubMedPubMedCentral
63.
Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf. 2013;12(2):177–86.CrossRefPubMed
64.
Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transpl Rev (Orlando, Fla). 2008;22(2):125–30.CrossRef
65.
Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation. 2006;82(3):368–74.CrossRefPubMed
66.
Wiseman AC, McCague K, Kim Y, Geissler F, Cooper M. The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. Am J Transpl. 2013;13(2):442–9.CrossRef
67.
Arnau A, Ruiz JC, Rodrigo E, Quintanar JA, Arias M. Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors? Transpl Proc. 2011;43(6):2194–5.CrossRef
68.
Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transpl. 2006;21(2):488–93.CrossRef
69.
Pelle G, Xu Y, Khoury N, Mougenot B, Rondeau E. Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am J Kidney Dis. 2005;46(6):1124–8.CrossRefPubMed
70.
Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transpl. 2005;5(10):2441–7.CrossRef
71.
Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2005;11(7):551–7.CrossRef
72.
Paramesh AS, Grosskreutz C, Florman SS, Gondolesi GE, Sharma S, Kaufman SS, et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation. 2004;77(1):129–31.CrossRefPubMed
73.
Lawsin L, Light JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation. 2003;75(1):157–60.CrossRefPubMed
74.
Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transpl. 2004;19(5):1288–92.CrossRef
75.
Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int. 2004;17(4):215–20.CrossRefPubMed
76.
Smith KD, Wrenshall LE, Nicosia RF, Pichler R, Marsh CL, Alpers CE, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol. 2003;14(4):1037–45.CrossRefPubMed
77.
Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med. 2005;353(19):2088–9.CrossRefPubMed
78.
Schonenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transpl. 2011;26(1):18–24.CrossRef
79.
Cina DP, Onay T, Paltoo A, Li C, Maezawa Y, De Arteaga J, et al. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol. 2012;23(3):412–20.CrossRefPubMedPubMedCentral
80.
Kirsch AH, Riegelbauer V, Tagwerker A, Rudnicki M, Rosenkranz AR, Eller K. The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. Am J Physiol Renal Physiol. 2012;303(4):F569–75.CrossRefPubMed
81.
Diekmann F, Andres A, Oppenheimer F. mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transpl Rev (Orlando, Fla). 2012;26(1):27–9.CrossRef
82.
Stallone G, Infante B, Pontrelli P, Gigante M, Montemurno E, Loverre A, et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation. 2011;91(9):997–1004.CrossRefPubMed
83.
Podder H, Podbielski J, Hussein I, Katz S, Van Buren C, Kahan BD. Sirolimus improves the two-year outcome of renal allografts in African-American patients. Transpl Int. 2001;14(3):135–42.CrossRefPubMed
84.
Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int. 2004;65(4):1262–71.CrossRefPubMed
85.
Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation. 1996;62(3):311–6.CrossRefPubMed
86.
Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Peraldi MN, Helal I, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol. 2007;2(2):326–33.CrossRefPubMed
87.
Christians U, Gottschalk S, Miljus J, Hainz C, Benet LZ, Leibfritz D, et al. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol. 2004;143(3):388–96.CrossRefPubMedPubMedCentral
88.
89.
Liu J, Liu D, Li J, Zhu L, Zhang C, Lei K, et al. Efficacy and safety of everolimus for maintenance immunosuppression of kidney transplantation: a meta-analysis of randomized controlled trials. PLoS One. 2017;12(1):e0170246.CrossRefPubMedPubMedCentral
90.
Sanchez-Fructuoso AI, Ruiz JC, Perez-Flores I, Gomez Alamillo C, Calvo Romero N, Arias M. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transpl Proc. 2010;42(8):3050–2.CrossRef
91.
Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116(1):210–5.PubMed
92.
Mahe E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005;79(4):476–82.CrossRefPubMed
93.
Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side effects of sirolimus therapy. Transplantation. 2009;87(8 Suppl):S23–6.CrossRefPubMed
94.
van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation. 2003;75(6):788–91.CrossRefPubMed
95.
Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol. 2013;49(4):293–8.CrossRefPubMed
96.
Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transpl. 2010;24(2):149–56.CrossRef
97.
Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016;27(3):519–25.CrossRefPubMedPubMedCentral
98.
Peterson DE, O’Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, et al. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016;5(8):1897–907.CrossRefPubMedPubMedCentral
99.
Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N. Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs. 2011;15(5):E83–9.CrossRefPubMed
100.
Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transpl. 2007;7(3):714–7.CrossRef
101.
Zuckermann A, Barten MJ. Surgical wound complications after heart transplantation. Transpl Int. 2011;24(7):627–36.CrossRefPubMed
102.
Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int. 2011;24(12):1216–30.CrossRefPubMed
103.
Tiong HY, Flechner SM, Zhou L, Wee A, Mastroianni B, Savas K, et al. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Transplantation. 2009;87(2):296–302.CrossRefPubMed
104.
Montalti R, Mimmo A, Rompianesi G, Serra V, Cautero N, Ballarin R, et al. Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation. Liver Transpl. 2012;18(2):188–94.CrossRefPubMed
105.
Mills RE, Taylor KR, Podshivalova K, McKay DB, Jameson JM. Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice. J Immunol (Baltimore, Md). 2008;181(6):3974–83.
106.
Squarize CH, Castilho RM, Bugge TH, Gutkind JS. Accelerated wound healing by mTOR activation in genetically defined mouse models. PLoS One. 2010;5(5):e10643.CrossRefPubMedPubMedCentral
107.
Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation. 2002;74(6):804–8.CrossRefPubMed
108.
Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, et al. Sirolimus-associated pulmonary toxicity. Transplantation. 2004;77(8):1215–20.CrossRefPubMed
109.
Baas MC, Struijk GH, Moes DJ, van den Berk IA, Jonkers RE, de Fijter JW, et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int. 2014;27(5):428–36.CrossRefPubMed
110.
Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study. Transplantation. 2015;99(7):1455–62.CrossRefPubMed
111.
Lopez P, Kohler S, Dimri S. Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: results from a large phase III clinical trial program of everolimus and review of the literature. J Transpl. 2014;2014:305931.
112.
Holdaas H, Midtvedt K, Asberg A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf. 2012;11(6):1013–22.CrossRefPubMed
113.
Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer (Oxford, England). 2011;47(9):1287–98.CrossRef
114.
Feagans J, Victor D, Moehlen M, Florman SS, Regenstein F, Balart LA, et al. Interstitial pneumonitis in the transplant patient: consider sirolimus-associated pulmonary toxicity. J La State Med Soc. 2009;161(3):166, 8–72.
115.
Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001;72(5):787–90.CrossRefPubMed
116.
Champion L, Stern M, Israel-Biet D, Mamzer-Bruneel MF, Peraldi MN, Kreis H, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med. 2006;144(7):505–9.CrossRefPubMed
117.
Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transpl Proc. 2006;38(3):711–3.CrossRef
118.
Morath C, Schwenger V, Ksoll-Rudek D, Sommerer C, Beimler J, Schmidt J, et al. Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors. Transpl Proc. 2007;39(1):99–102.CrossRef
119.
Garrean S, Massad MG, Tshibaka M, Hanhan Z, Caines AE, Benedetti E. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transpl. 2005;19(5):698–703.CrossRef
120.
Rodriguez-Pascual J, Cheng E, Maroto P, Duran I. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anti-cancer Drugs. 2010;21(5):478–86.CrossRefPubMed
121.
Filippone EJ, Carson JM, Beckford RA, Jaffe BC, Newman E, Awsare BK, et al. Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report. Transpl Proc. 2011;43(7):2792–7.CrossRef
122.
123.
Wadei H, Gruber SA, El-Amm JM, Garnick J, West MS, Granger DK, et al. Sirolimus-induced angioedema. Am J Transpl. 2004;4(6):1002–5.CrossRef
124.
Burdese M, Rossetti M, Guarena C, Consiglio V, Mezza E, Soragna G, et al. Sirolimus and ACE-inhibitors: a note of caution. Transplantation. 2005;79(2):251–2.CrossRefPubMed
125.
Stallone G, Infante B, Di Paolo S, Schena A, Grandaliano G, Gesualdo L, et al. Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transpl. 2004;19(11):2906–8.CrossRef
126.
Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation. 2001;72(1):162–4.CrossRefPubMed
127.
Romagnoli J, Citterio F, Nanni G, Tondolo V, Castagneto M. Severe limb lymphedema in sirolimus-treated patients. Transpl Proc. 2005;37(2):834–6.CrossRef
128.
129.
Desai N, Heenan S, Mortimer PS. Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism. Br J Dermatol. 2009;160(6):1322–6.CrossRefPubMed
130.
Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71(8):771–7.CrossRefPubMed
131.
Al-Otaibi T, Ahamed N, Nampoory MR, Al-Kandari N, Nair P, Hallm MA, et al. Lymphedema: an unusual complication of sirolimus therapy. Transpl Proc. 2007;39(4):1207–10.CrossRef
132.
Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(2):157–63.CrossRefPubMed
133.
Omarini C, Filieri ME, Depenni R, Grizzi G, Cascinu S, Piacentini F. Osteonecrosis of the jaw in a breast cancer patient treated with everolimus and a single dose of zoledronic acid. Breast J. 2017;23(5):610–1.CrossRefPubMed
134.
Kubo T, Fujioka M, Yamazoe S, Yoshimura N, Oka T, Ushijima Y, et al. Relationship between steroid dosage and osteonecrosis of the femoral head after renal transplantation as measured by magnetic resonance imaging. Transpl Proc. 1998;30(7):3039–40.CrossRef
135.
Bhandari S, Eris J. Drug points: Premature osteonecrosis and sirolimus treatment in renal transplantation. BMJ (Clin Res Ed). 2001;323(7314):665.CrossRef
136.
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2013;381(9861):125–32.CrossRef
137.
Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2013;381(9869):817–24.CrossRef
138.
Boobes Y, Bernieh B, Saadi H, Raafat Al Hakim M, Abouchacra S. Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus. Int Urol Nephrol. 2010;42(2):493–8.CrossRefPubMed
Metadata
Title
Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation
Authors
Lee S. Nguyen
Mathieu Vautier
Yves Allenbach
Noel Zahr
Olivier Benveniste
Christian Funck-Brentano
Joe-Elie Salem
Publication date
01-07-2019
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 7/2019
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-019-00810-9

Other articles of this Issue 7/2019

Drug Safety 7/2019 Go to the issue

Short Communication

Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study

Short Communication

Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis

Original Research Article

Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study

Research Letter

A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia

Review Article

Drug-Induced Photosensitivity—An Update: Culprit Drugs, Prevention and Management

Original Research Article

Use of FDA’s Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure